Alzheimer's Disease Biomarker Analysis Using Targeted Mass Spectrometry

Overview

Journal Mol Cell Proteomics

Specialties Biochemistry
Cell Biology
Molecular Biology

Date 2024 Jan 21

PMID 38246483

Authors

Johan Gobom

Ann Brinkmalm

Gunnar Brinkmalm

Kaj Blennow

Henrik Zetterberg

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is characterized by several neuropathological changes, mainly extracellular amyloid aggregates (plaques), intraneuronal inclusions of phosphorylated tau (tangles), as well as neuronal and synaptic degeneration, accompanied by tissue reactions to these processes (astrocytosis and microglial activation) that precede neuronal network disturbances in the symptomatic phase of the disease. A number of biomarkers for these brain tissue changes have been developed, mainly using immunoassays. In this review, we discuss how targeted mass spectrometry (TMS) can be used to validate and further characterize classes of biomarkers reflecting different AD pathologies, such as tau- and amyloid-beta pathologies, synaptic dysfunction, lysosomal dysregulation, and axonal damage, and the prospect of using TMS to measure these proteins in clinical research and diagnosis. TMS advantages and disadvantages in relation to immunoassays are discussed, and complementary aspects of the technologies are discussed.

Citing Articles

FLIM-Phasor Analysis (FLIM-ϕ) of Aβ-Induced Membrane Order Alterations: Towards a Cell-Based Biosensor for Early Alzheimer's Disease Diagnosis.

Battisti A, Ortore M, Vilasi S, Sgarbossa A Micromachines (Basel). 2025; 16(2).

PMID: 40047700 PMC: 11857758. DOI: 10.3390/mi16020234.

Mass Spectrometry Advancements and Applications for Biomarker Discovery, Diagnostic Innovations, and Personalized Medicine.

Son A, Kim W, Park J, Park Y, Lee W, Lee S Int J Mol Sci. 2024; 25(18).

PMID: 39337367 PMC: 11432749. DOI: 10.3390/ijms25189880.

Clinical Proteomics: A Promise Becoming Reality.

Gillette M, Jimenez C, Carr S Mol Cell Proteomics. 2024; 23(2):100688.

PMID: 38281326 PMC: 10926064. DOI: 10.1016/j.mcpro.2023.100688.

References

Hanger D, Betts J, Loviny T, Blackstock W, Anderton B . New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J Neurochem. 1998; 71(6):2465-76. DOI: 10.1046/j.1471-4159.1998.71062465.x. View

Brureau A, Blanchard-Bregeon V, Pech C, Hamon S, Chaillou P, Guillemot J . NF-L in cerebrospinal fluid and serum is a biomarker of neuronal damage in an inducible mouse model of neurodegeneration. Neurobiol Dis. 2017; 104:73-84. DOI: 10.1016/j.nbd.2017.04.007. View

Camporesi E, Nilsson J, Vrillon A, Cognat E, Hourregue C, Zetterberg H . Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry. EBioMedicine. 2022; 75:103793. PMC: 8743209. DOI: 10.1016/j.ebiom.2021.103793. View

Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B . Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol. 2001; 58(3):373-9. DOI: 10.1001/archneur.58.3.373. View

Molin P, Rockwood K . The New Criteria for Alzheimer's Disease - Implications for Geriatricians. Can Geriatr J. 2016; 19(2):66-73. PMC: 4922370. DOI: 10.5770/cgj.19.207. View

Simon R, Girod M, Fonbonne C, Salvador A, Clement Y, Lanteri P . Total ApoE and ApoE4 isoform assays in an Alzheimer's disease case-control study by targeted mass spectrometry (n=669): a pilot assay for methionine-containing proteotypic peptides. Mol Cell Proteomics. 2012; 11(11):1389-403. PMC: 3494189. DOI: 10.1074/mcp.M112.018861. View

Henderson M, Trojanowski J, Lee V . α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies. Neurosci Lett. 2019; 709:134316. PMC: 7014913. DOI: 10.1016/j.neulet.2019.134316. View

Duits F, Brinkmalm G, Teunissen C, Brinkmalm A, Scheltens P, van der Flier W . Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease. Alzheimers Res Ther. 2018; 10(1):5. PMC: 6389073. DOI: 10.1186/s13195-017-0335-x. View

Kvartsberg H, Duits F, Ingelsson M, Andreasen N, Ohrfelt A, Andersson K . Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. Alzheimers Dement. 2014; 11(10):1180-90. DOI: 10.1016/j.jalz.2014.10.009. View

10.

Ishiguro K, Ohno H, Arai H, Yamaguchi H, Urakami K, Park J . Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease. Neurosci Lett. 1999; 270(2):91-4. DOI: 10.1016/s0304-3940(99)00476-0. View

11.

Schindler S, Bollinger J, Ovod V, Mawuenyega K, Li Y, Gordon B . High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019; 93(17):e1647-e1659. PMC: 6946467. DOI: 10.1212/WNL.0000000000008081. View

12.

Terry R, Masliah E, Salmon D, Butters N, DeTeresa R, Hill R . Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991; 30(4):572-80. DOI: 10.1002/ana.410300410. View

13.

Dumurgier J, Schraen S, Gabelle A, Vercruysse O, Bombois S, Laplanche J . Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study. Alzheimers Res Ther. 2015; 7(1):30. PMC: 4450486. DOI: 10.1186/s13195-015-0114-5. View

14.

Karikari T, Emersic A, Vrillon A, Lantero-Rodriguez J, Ashton N, Gregoric Kramberger M . Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis. Alzheimers Dement. 2020; 17(5):755-767. PMC: 8246793. DOI: 10.1002/alz.12236. View

15.

Barthelemy N, Fenaille F, Hirtz C, Sergeant N, Schraen-Maschke S, Vialaret J . Tau Protein Quantification in Human Cerebrospinal Fluid by Targeted Mass Spectrometry at High Sequence Coverage Provides Insights into Its Primary Structure Heterogeneity. J Proteome Res. 2016; 15(2):667-76. DOI: 10.1021/acs.jproteome.5b01001. View

16.

Mattsson N, Rajendran L, Zetterberg H, Gustavsson M, Andreasson U, Olsson M . BACE1 inhibition induces a specific cerebrospinal fluid β-amyloid pattern that identifies drug effects in the central nervous system. PLoS One. 2012; 7(2):e31084. PMC: 3273469. DOI: 10.1371/journal.pone.0031084. View

17.

Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M . CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2016; 15(7):673-684. DOI: 10.1016/S1474-4422(16)00070-3. View

18.

Holtta M, Minthon L, Hansson O, Holmen-Larsson J, Pike I, Ward M . An integrated workflow for multiplex CSF proteomics and peptidomics-identification of candidate cerebrospinal fluid biomarkers of Alzheimer's disease. J Proteome Res. 2014; 14(2):654-63. DOI: 10.1021/pr501076j. View

19.

Nilsson J, Gobom J, Sjodin S, Brinkmalm G, Ashton N, Svensson J . Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease. Alzheimers Dement (Amst). 2021; 13(1):e12179. PMC: 8087978. DOI: 10.1002/dad2.12179. View

20.

Pannee J, Tornqvist U, Westerlund A, Ingelsson M, Lannfelt L, Brinkmalm G . The amyloid-β degradation pattern in plasma--a possible tool for clinical trials in Alzheimer's disease. Neurosci Lett. 2014; 573:7-12. DOI: 10.1016/j.neulet.2014.04.041. View